Nejčastějším histologickým typem nádorů močového měchýře je uroteliální karcinom. Chemoterapeutické režimy pro metastazující onemocnění jsou založeny na platinových derivátech. Pro nemocné s lokálně pokročilou nebo metastazující chorobou je novou léčebnou možností imunoterapie.

The most particular histological type of bladder cancer is urothelial carcinoma. The chemotherapeutic schedules for metastatic disease are based on derivatives of platinum. The imunotherapy is novel therapeutic possibility for patients with local advanced and metastatic disease.

• Keywords
• Javlor,
• MeSH
• Survival Analysis MeSH
• Programmed Cell Death 1 Ligand 2 Protein drug effects   MeSH
• B7-H1 Antigen drug effects   MeSH
• Cisplatin adverse effects   therapeutic use   MeSH
• Carcinoma, Transitional Cell drug therapy   MeSH
• Humans MeSH
• Antibodies, Monoclonal administration & dosage   adverse effects   MeSH
• Urinary Bladder Neoplasms * drug therapy   pathology   MeSH
• Antineoplastic Combined Chemotherapy Protocols MeSH
• Platinum Compounds adverse effects   therapeutic use   MeSH
• Neoplasm Grading MeSH
• Vinblastine analogs & derivatives   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Clinical Study MeSH

• MeSH
• Survival Analysis MeSH
• Programmed Cell Death 1 Ligand 2 Protein genetics   immunology   drug effects   MeSH
• Antibodies, Monoclonal, Humanized administration & dosage   MeSH
• Immunotherapy MeSH
• Humans MeSH
• Carcinoma, Non-Small-Cell Lung * drug therapy   immunology   MeSH
• Drug Administration Schedule MeSH
• Taxoids administration & dosage   MeSH
• Check Tag
• Humans MeSH

• MeSH
• CTLA-4 Antigen isolation & purification   drug effects   MeSH
• Programmed Cell Death 1 Ligand 2 Protein isolation & purification   drug effects   MeSH
• B7-H1 Antigen isolation & purification   drug effects   MeSH
• Programmed Cell Death 1 Receptor antagonists & inhibitors   MeSH
• Biomarkers * blood   MeSH
• Biopsy methods   utilization   MeSH
• Cytokines isolation & purification   blood   MeSH
• Interferon-gamma isolation & purification   MeSH
• Ipilimumab MeSH
• Carcinoma, Renal Cell * drug therapy   secondary   therapy   MeSH
• Clinical Trials, Phase I as Topic MeSH
• Congresses as Topic MeSH
• Humans MeSH
• Antibodies, Monoclonal * therapeutic use   toxicity   drug effects   MeSH
• Kidney Neoplasms drug therapy   secondary   therapy   MeSH
• Nivolumab MeSH
• Receptors, Antigen, T-Cell isolation & purification   blood   drug effects   MeSH
• Gene Expression Regulation genetics   immunology   drug effects   MeSH
• Statistics as Topic MeSH
• Check Tag
• Humans MeSH